Imetelstat for anemia in lower-risk myelodysplastic syndromes: A summary from the Institute for Clinical and Economic Review's California Technology Assessment Forum.
作者信息
Fahim Shahariar Mohammed, Tice Jeffrey A, Luu Linda, Carlson Josh J, Richardson Marina, Herce-Hagiwara Belen, Dickerson Ronald, Ollendorf Daniel A
机构信息
Institute for Clinical and Economic Review, Boston, MA.
Division of General Internal Medicine, University of California San Francisco.
出版信息
J Manag Care Spec Pharm. 2024 Dec;30(12):1479-1485. doi: 10.18553/jmcp.2024.30.12.1479.
Abstract
摘要
相似文献
1
Imetelstat for anemia in lower-risk myelodysplastic syndromes: A summary from the Institute for Clinical and Economic Review's California Technology Assessment Forum.艾美司他用于低危骨髓增生异常综合征贫血：来自临床与经济审评学会加利福尼亚技术评估论坛的总结
J Manag Care Spec Pharm. 2024 Dec;30(12):1479-1485. doi: 10.18553/jmcp.2024.30.12.1479.
2
The effectiveness and value of lecanemab for early Alzheimer disease: A summary from the Institute for Clinical and Economic Review's California Technology Assessment Forum.乐卡奈单抗用于早期阿尔茨海默病的有效性和价值：来自临床与经济评论研究所加利福尼亚技术评估论坛的总结
J Manag Care Spec Pharm. 2023 Sep;29(9):1078-1083. doi: 10.18553/jmcp.2023.29.9.1078.
3
The effectiveness and value of gene therapy for hemophilia: A Summary from the Institute for Clinical and Economic Review's California Technology Assessment Forum.基因治疗血友病的效果和价值：来自加州技术评估论坛临床与经济评论研究所的总结。
J Manag Care Spec Pharm. 2023 May;29(5):576-581. doi: 10.18553/jmcp.2023.29.5.576.
4
Imetelstat in myeloid malignancies: current data and future directions.艾美司他在髓系恶性肿瘤中的应用：当前数据与未来方向。
Expert Rev Anticancer Ther. 2025 May;25(5):517-528. doi: 10.1080/14737140.2025.2482721. Epub 2025 Mar 28.
5
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.Imetelstat用于复发或对促红细胞生成素刺激剂难治的低危骨髓增生异常综合征患者（IMerge）：一项多中心、随机、双盲、安慰剂对照的3期试验。
Lancet. 2024 Jan 20;403(10423):249-260. doi: 10.1016/S0140-6736(23)01724-5. Epub 2023 Dec 1.
6
Imetelstat: Finally a disease-modifying treatment for lower-risk myelodysplastic syndromes?依特司他：低危骨髓增生异常综合征的首款靶向药物？
Med. 2024 Mar 8;5(3):184-186. doi: 10.1016/j.medj.2024.01.004.
7
Imetelstat: First Approval.依美替萨：美国获批。
Drugs. 2024 Sep;84(9):1149-1155. doi: 10.1007/s40265-024-02080-x. Epub 2024 Aug 20.
8
Examining the safety and efficacy of imetelstat in low-risk myelodysplastic syndrome.研究艾美替尼在低危骨髓增生异常综合征中的安全性和有效性。
Expert Opin Pharmacother. 2025 Apr;26(5):525-533. doi: 10.1080/14656566.2025.2471518. Epub 2025 Feb 27.
9
Imetelstat (Rytelo) for myelodysplastic syndromes.用于骨髓增生异常综合征的艾美司他（Rytelo）
Med Lett Drugs Ther. 2024 Sep 30;66(1712):e169-e170. doi: 10.58347/tml.2024.1712d.
10
Imetelstat, a novel, first-in-class telomerase inhibitor: Mechanism of action, clinical, and translational science.依特司他，一种新型的首创端粒酶抑制剂：作用机制、临床和转化科学。
Clin Transl Sci. 2024 Nov;17(11):e70076. doi: 10.1111/cts.70076.
本文引用的文献
1
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.骨髓增生异常综合征的分子国际预后评分系统
NEJM Evid. 2022 Jul;1(7):EVIDoa2200008. doi: 10.1056/EVIDoa2200008. Epub 2022 Jun 12.
2
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.Imetelstat用于复发或对促红细胞生成素刺激剂难治的低危骨髓增生异常综合征患者（IMerge）：一项多中心、随机、双盲、安慰剂对照的3期试验。
Lancet. 2024 Jan 20;403(10423):249-260. doi: 10.1016/S0140-6736(23)01724-5. Epub 2023 Dec 1.
3
Diagnosis and classification of myelodysplastic syndromes.骨髓增生异常综合征的诊断和分类。
Blood. 2023 Dec 28;142(26):2247-2257. doi: 10.1182/blood.2023020078.
4
Economic Impact of Transformation to Acute Myeloid Leukemia Among Actively Managed Patients with Higher-Risk Myelodysplastic Syndromes in the United States.美国高危骨髓增生异常综合征患者积极管理下向急性髓系白血病转化的经济影响。
Adv Ther. 2023 Apr;40(4):1655-1669. doi: 10.1007/s12325-022-02370-4. Epub 2022 Nov 24.
5
A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry.环形铁幼粒细胞骨髓增生异常综合征的自然病史：MDS-CAN 登记处的分析。
Leuk Lymphoma. 2022 Dec;63(13):3165-3174. doi: 10.1080/10428194.2022.2109154. Epub 2022 Sep 12.
6
Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts.来苏特生对伴有环形铁粒幼细胞的输血依赖型低危骨髓增生异常综合征的长期益处。
Blood. 2022 Nov 17;140(20):2170-2174. doi: 10.1182/blood.2022016171.
7
Patient and Caregiver Insights into the Disease Burden of Myelodysplastic Syndrome.患者及照料者对骨髓增生异常综合征疾病负担的见解
Patient Relat Outcome Meas. 2022 Feb 4;13:31-38. doi: 10.2147/PROM.S346434. eCollection 2022.
8
Association between red blood cell transfusion dependence and burden in patients with myelodysplastic syndromes: A systematic literature review and meta-analysis.骨髓增生异常综合征患者红细胞输血依赖与负担的相关性：系统文献回顾和荟萃分析。
Eur J Haematol. 2021 Jul;107(1):3-23. doi: 10.1111/ejh.13619. Epub 2021 Apr 14.
9
Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes.新诊断的低危骨髓增生异常综合征患者中环形铁幼粒细胞和 SF3B1 突变评估的真实世界诊断检测模式。
Int J Lab Hematol. 2021 Jun;43(3):426-432. doi: 10.1111/ijlh.13400. Epub 2020 Nov 21.
10
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.芦可替尼治疗低危骨髓增生异常综合征患者的疗效。
N Engl J Med. 2020 Jan 9;382(2):140-151. doi: 10.1056/NEJMoa1908892.
Zotero 插件